Clinical trials: Philadelphia Negative Myeloproliferative Neoplasms
Thrombosis
Risk Factors and Predictors of Thrombosis in Myeloprolferative Neoplasms
To assess the clinical risk factors and predictable biomarkers of thrombotic complications in cases of philadelphia negative myeloproliferative disorders.
- Trial name
- NCT03599700
- Testing
- myeloproliferative neoplasms
- Where
- Egypt
- Volunteers
- 165 people
- Sponsor
- Assiut University
Leukemia
Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00002771
- Testing
- recombinant interferon alfa, busulfan, cytarabine
- Where
- Germany
- Volunteers
- 750 people
- Sponsor
- German CML Study Group
Accelerated Phase of Disease, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
This phase I trial is studying the side effects and best dose of belinostat when given together with azacitidine in treating patients with advanced hematologic cancers or other diseases.
- Conditions
- Accelerated Phase of Disease, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1
- Trial name
- NCT00351975
- Testing
- Belinostat, Azacitidine, Laboratory Biomarker Analysis
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 56 people
- Sponsor
- National Cancer Institute (NCI)
Hematologic Diseases
Registry of Philadelphia-Negative Myeloproliferative Neoplasms
This study was developed to document current diagnosis and treatment patterns, clinical outcomes, and health care resource use associated with Philadelphia-Negative Myeloproliferative Neoplasms, in the different risk…
- Trial name
- MPN (NCT02380378)
- Where
- Brazil
- Volunteers
- 500 people
- Sponsor
- Hospital Israelita Albert Einstein
Leukemia
Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's…
- Trial name
- NCT00003561
- Testing
- recombinant interferon alfa, sargramostim
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Myeloproliferative Neoplasm
PREVALENCE STUDY OF PNH CLONES IN PATIENTS WITH NEOPLASIES
Multicenter prevalence study of the PNH clone (paroxysmal hemoglobinuria nocturnal) in SMP Ph-. This multicenter, prospective study aims to evaluate the presence of an PNH clone in patients with a confirmed diagnosis of…
- Trial name
- NCT06159816
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- AUSL Romagna Rimini
Leukemia
STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia
RATIONALE: STI571 may interfere with the growth of cancer cells and may be effective treatment for chronic myelogenous leukemia.
- Trial name
- NCT00006052
- Testing
- imatinib mesylate
- Where
- United States
- Sponsor
- Novartis